Prostate Specific Antigen (PSA) Derivatives for Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia Subjects in Sokoto, Nigeria
Published on: 2018-08-01
Over the years, many markers have been used for the diagnosis and follow-up of prostate disorders. With its attendant limitations, PSA is the most common marker used. In the present study, PSA ratios; fPSA/cPSA, fPSA/tPSA and cPSA/tPSA were evaluated in 150 prostate cancer (PCa), 200 benign hyperplasia (BPH) patients and 200 controls. Using Mann-Whitney U-Test, free PSA/complexPSA ratio (fPSA/cPSA) was 0. 18±0.01, 0.34±0.02, 0.48±0.02, freePSA/totalPSA ratio (fPSA/tPSA) was 0.19±0.11, 0.34±0.23 and 0.48±0.23 while complexPSA/totalPSA ratio (cPSA/tPSA) was 0.85±0.01, 0.7±0.01 and 0.70±0.01 in PCa, BPH and controls respectively. The difference in the ratios between all the groups are significant (p<0.01). Evidence from the current study suggested that, diagnosis and prognosis of prostate disorders can be widened and more steps need to be taken to determine the efficacy of these markers.
PSA: Prostate Specific Antigen (PSA) ratios; PCa: Prostate cancer (PCa); BPH: Benign prostatic hyperplasia (BPH); diagnostic value